Interferon-induced Raynaud's syndrome
- PMID: 12528080
- DOI: 10.1053/sarh.2002.34606
Interferon-induced Raynaud's syndrome
Abstract
Objective: To review the clinical features, diagnosis, treatment, and outcome of interferon-induced Raynaud's phenomenon.
Methods: The medical literature was reviewed from 1967 to November 2001 with the assistance of a MEDLINE search using the key words: Raynaud, Interferon, ischemia, thrombosis and necrosis. A qualitative review was performed after the articles were abstracted and the relevant information was summarized.
Results: Twenty-four cases of interferon-induced Raynaud's phenomenon (including our patient) are described. Interpheron-alpha was the most common causative agent (14 cases). The symptoms appeared weeks to years after beginning treatment and varied from mild vasospasm to occlusion of digital arteries and tissue necrosis (14 cases), sometimes necessitating finger amputation (6 patients). Digital plethysmography, arteriography and capillaroscopy were valuable diagnostic tools. In 4 cases, cardiac, ophthalmic, or central nervous system drug-induced ischemia accompanied the peripheral Raynaud's phenomenon. Of the 15 cases with a documented outcome, withdrawal of the drug alone resulted in complete (6 patients) or partial (1 patient) recovery. In the others, supportive therapy was needed. The recovery period lasted from 2 weeks to 3 months. In 2 patients, continuation of treatment was possible.
Conclusions: Raynaud's phenomenon and related complications must be recognized as possible side effects of interferon therapy. Early diagnosis and withdrawal of the drug may prevent unnecessary morbidity and disability.
Copyright 2002, Elsevier Science (USA). All rights reserved.
Similar articles
-
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.Circulation. 2005 Nov 8;112(19):2980-5. doi: 10.1161/CIRCULATIONAHA.104.523324. Circulation. 2005. PMID: 16275885 Clinical Trial.
-
Raynaud's phenomenon and digital necrosis induced by interferon-alpha.Br J Dermatol. 1996 Sep;135(3):481-3. Br J Dermatol. 1996. PMID: 8949451
-
Treatment of Raynaud's phenomenon.Autoimmun Rev. 2008 Oct;8(1):62-8. doi: 10.1016/j.autrev.2008.07.002. Epub 2008 Aug 8. Autoimmun Rev. 2008. PMID: 18692160 Review.
-
Raynaud's syndrome: diagnosis and treatment.J Vasc Nurs. 1994 Mar;12(1):10-3. J Vasc Nurs. 1994. PMID: 7748770
-
Raynaud's phenomenon.J Vasc Nurs. 2001 Sep;19(3):87-92; quiz 93-4. doi: 10.1067/mvn.2001.117786. J Vasc Nurs. 2001. PMID: 11533581 Review.
Cited by
-
Ocular side effects of biological agents in oncology: what should the clinician be aware of?Onco Targets Ther. 2013 Dec 24;7:69-77. doi: 10.2147/OTT.S54606. Onco Targets Ther. 2013. PMID: 24391443 Free PMC article. Review.
-
A challenging entity: multiple sclerosis or collagen tissue disorders: A case series of 6 patients.Caspian J Intern Med. 2017 Fall;8(4):321-328. doi: 10.22088/cjim.8.4.321. Caspian J Intern Med. 2017. PMID: 29201326 Free PMC article.
-
Unveiling the Enigma: Idiopathic Digital Infarction-A Case Report and Literature Review.Clin Case Rep. 2025 Jan 30;13(2):e70107. doi: 10.1002/ccr3.70107. eCollection 2025 Feb. Clin Case Rep. 2025. PMID: 39895848 Free PMC article.
-
Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis.Rheumatol Int. 2008 May;28(7):703-7. doi: 10.1007/s00296-007-0507-2. Epub 2007 Dec 8. Rheumatol Int. 2008. PMID: 18066551
-
Digital ischemia associated with cancer: results from a cohort study.Medicine (Baltimore). 2014 Aug;93(10):e47. doi: 10.1097/MD.0000000000000047. Medicine (Baltimore). 2014. PMID: 25170929 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical